Cinryze™ C1 Inhibitor (human)
The following information is intended for use by viewers in the United States
Cinryze™ C1 Esterase Inhibitor (human) is an FDA-approved C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). Cinryze is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.
View full package insert here
Cinryze C1 Esterase Inhibitor (human) is for intravenous use only. A dose of 1000 Units CINRYZE can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients.
Cinryze C1 Esterase Inhibitor (human) is administered at an injection rate of 1 mL per minute
Severe hypersensitivity reactions may occur. Because hypersensitivity reactions and HAE attacks may have similar symptoms, distinguishing between the two is important. Epinephrine should be immediately available to treat any acute severe hypersensitivity reaction and CINRYZE™ should be discontinued. Thrombotic events have been reported in association with other C1 esterase inhibitor products when used off-label at high doses. Monitor patients with known risk factors for thrombotic events.
Cinryze is made from human plasma. Products made from human plasma may contain infectious agents (e.g. viruses and, theoretically, the Creutzfeldt-Jakob Disease agent). The risk that such products will transmit an infectious agent has been reduced by screening donors, testing for the presence of infections, and by inactivating or removing a broad range of viruses during the manufacturing process. In the clinical trial, the most common adverse reactions observed by ≥ 5% of the 24 evaluable subjects after receiving Cinryze were upper respiratory tract infection, sinusitis, rash, and headache. Before prescribing Cinryze, please read the Full Prescribing Information, which can be accessed here.